COX-2, OTC Analgesics Safety Should Not Be "Blurred," NDMA Urges Cmte.
This article was originally published in The Tan Sheet
Executive Summary
FDA's Arthritis Advisory Committee should "avoid the blurring of the comparative safety of the COX-2 inhibitors with OTC analgesics" in its recommendation for Searle/Pfizer's Celebrex (celecoxib) precription analgesic agent, NDMA Senior VP William Soller, PhD, urged during the committee's Dec. 1 consider-ation of the drug for Rx status. NDMA said it was concerned the lay media could create confusion between Celebrex and OTC analgesics.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning